Sublingual allergen immunotherapy for respiratory allergies: what is new?

References

• Cox L. Sublingual immunotherapy for aeroallergens: status in the United States. Allergy Asthma Proc 2014;35(1):34-42
   PubMed Web of Science ®Google Scholar
• Approval Letter-RAGWITEK, Food and drug administration. 2014. Available from: www.fda.gov/BiologicsBloodVaccines/Allergenics/ucm393806.htm [Last accessed 4 September 2014]
   Google Scholar
• Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: world allergy organization position paper 2013 update. World Allergy Organ J 2014;7(1):6
   PubMedGoogle Scholar
• Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013;131(5):1288-96
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129(3):717-25
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013;43(5):568-77
   PubMed Web of Science ®Google Scholar
• Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014;112(2):146-53
   PubMed Web of Science ®Google Scholar
• Nelson H, Blaiss M, Nolte H, et al. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy 2013;68(2):252-5
   PubMed Web of Science ®Google Scholar
• Wahn U, Klimek L, Ploszczuk A, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2012;130(4):886-93
   PubMed Web of Science ®Google Scholar
• Stelmach I, Kaluzińska-Parzyszek I, Jerzynska J, et al. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy 2012;67(3):312-20
   PubMed Web of Science ®Google Scholar
• Karagiannis E, Shah-Hosseini K, Hadler M, et al. Non-interventional 2-year study of sublingual immunotherapy in children and adolescents with allergic rhinoconjunctivitis caused by grass pollen. Clin Transl Allergy 2014;4(Suppl 1):P14
   PubMedGoogle Scholar
• Klimek L, Sperl A, van Twuijver E, et al. A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. Clin Transl Allergy 2014;4:23
   PubMed Web of Science ®Google Scholar
• Marogna M, Braidi C, Bruno ME, et al. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial. Allergol Immunopathol (Madr) 2013;41(4):216-24
   PubMed Web of Science ®Google Scholar
• Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 2014;133(6):1608-14
   PubMed Web of Science ®Google Scholar
• Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134:568-75
   PubMed Web of Science ®Google Scholar
• de Blay F, Kuna P, Prieto L, et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma - Post hoc results from a randomised trial. Respir Med 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Wang L, Yin J, Fadel R, et al. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy 2014;69(9):1181-8
   PubMed Web of Science ®Google Scholar
• Wang DH, Chen L, Cheng L, et al. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicentre, randomized, double-blind, placebo-controlled trial. Laryngoscope 2013;123(6):1334-40
   PubMed Web of Science ®Google Scholar
• Li P, Li Q, Huang Z, et al. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. Int Forum Allergy Rhinol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Bozek A, Ignasiak B, Filipowska B, et al. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy 2013;43(2):242-8
   PubMed Web of Science ®Google Scholar
• Nolte H, Hébert J, Berman G, et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol 2013;110(6):450-6
   PubMed Web of Science ®Google Scholar
• Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 2013;131(5):1342-9
   PubMed Web of Science ®Google Scholar
• Nolte H, Amar N, Bernstein DI, et al. Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Ann Allergy Asthma Immunol 2014;113(1):93-100
   PubMed Web of Science ®Google Scholar
• Creticos PS, Esch RE, Couroux P, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol 2014;133(3):751-8
   PubMed Web of Science ®Google Scholar
• Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013;309:1278-88
   PubMed Web of Science ®Google Scholar
• Devillier P, Dreyfus JF, Demoly P, et al. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med 2014;12:71
   PubMed Web of Science ®Google Scholar
• Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014;69(7):854-67
   PubMed Web of Science ®Google Scholar
• Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol 2014;14:363-70
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Oradei M, Frati F, et al. Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults. Clin Drug Investig 2013;33(5):343-9
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. J Eval Clin Pract 2014;20:225-38
   PubMed Web of Science ®Google Scholar
• Bender BG, Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. J Allergy Clin Immunol Pract 2014;2(2):152-5
   PubMed Web of Science ®Google Scholar
• Kiel MA, Röder E, Gerth van Wijk R, et al. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013;132(2):353-60
   PubMed Web of Science ®Google Scholar
• Antico A. Long-term-adherence to sublingual therapy: literature review and suggestions for management strategies based on patients’ needs and preferences. Clin Exp Allergy 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124(3):471-7
   PubMed Web of Science ®Google Scholar
• Nolte H, Maloney J, Nelson HS, et al. Dose-finding efficacy and safety trial of the house dust mite sublingual immunotherapy tablet, mk-8237, using an environmental exposure chamber. JACI 2014;133(2 Supplement):AB403
   Web of Science ®Google Scholar
• Meyer W, Narkus A, Salapatek AM, et al. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy 2013;68(6):724-31
   PubMed Web of Science ®Google Scholar
• Patel P, Holdich T, Fischer von Weikersthal-Drachenberg KJ, et al. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol 2014;133(1):121-9
   PubMed Web of Science ®Google Scholar
• Patel D, Couroux P, Hickey P. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013;131(1):103-9
   PubMed Web of Science ®Google Scholar
• Hashiguchi K, Tang H, Fujita T, et al. Validation study of the OHIO Chamber in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol 2009;149(2):141-9
   PubMed Web of Science ®Google Scholar
• Zieglmayer PU. Are results of environmental exposure units transferable to real-life exposure? Curr Opin Allergy Clin Immunol 2013;13(3):244-8
   PubMed Web of Science ®Google Scholar
• Devillier P, Le Gall M, Horak F. The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy. Allergy 2011;66(2):163-9
   PubMed Web of Science ®Google Scholar
• Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy. Curr Allergy Asthma Rep 2014;14(11):473
   PubMed Web of Science ®Google Scholar
• Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract 2013;1(3):228-41
   PubMed Web of Science ®Google Scholar